(Boursier.com) — GenSight Biologicsa biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies for the treatment of neurodegenerative diseases of the retina and central nervous system, announces the holding of its Combined General Meeting on May 29, 2024 at 9:00 a.m. at the Company’s head office, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.
©2024 Boursier.com